Dave brings 20 years of experience working with Fortune 500 and biotech executive teams on R&D portfolio management / strategy, product commercialization, and business development. While the span of his work includes all major therapeutic areas, particular areas of focus have included oncology, hematology, immunology, and pulmonology including orphan disease sub-segments.
Prior to joining Clearview, Dave led business development & strategy for Surface Oncology, a publicly traded immuno-oncology biotech. Before Surface, he had responsibility for worldwide commercial strategy for Bristol-Myers Squibb’s immuno-oncology portfolio which saw over 200 approvals across 50+ countries in ~3 years. Dave also brings extensive management consulting experience having served on the leadership team of The Frankel Group, now part of Huron Consulting, and in the life sciences practice of Deloitte Consulting.
Dave holds a B.S. in Computer Science and Business from Muhlenberg College and an MBA in Finance and Healthcare from the Wharton School of Business.
Seth Berman
Klaus Bredl
Steven Chao
Rishi Dalsania
David Gilman
Ketan Kapadia
Philip Kenner
David McClain
Richard Mynahan
Kevin Richard
Sam Ulin
Debbie Zhuang
Sidnee Pinho
Kristine Hyde
Steve Rubman
Debbi Amanti Belanger
Kim Goh
Slater Hurst
Dave Konciak
Charles Mathews
Mike Rizzo
Mike Roy
Ryan Tubman
Beko Binder
Jonny Betts
Dean Griffiths
Maneesh Gujrati
Austin Hubbert
Jonathan Hodgson
Owen Im
Jonny Juliano
Andrew Kang
Joanna Lee
Alexander Lehrman
Alec Marchuk
Matthew Murphy
Mike Murray
Olivia Piccione
Matthew Pfister
Kai-Ming Pu
Sarah Stapleton
Kelsey Yardumian